SEC Form 4 · accession 0001225208-18-004488
PFIZER INC · PFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian C Read
Officer — Chairman & CEO · Director
Period of report
Feb 24, 2018
Accepted (ET)
Feb 27, 2018 · 8:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000078003
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 24, 2018 | M | 483,559 | $18.90 | A | 1,140,007 | D | |
| Common StockF1 | Feb 24, 2018 | M | 420,000 | $20.90 | A | 1,560,007 | D | |
| Common StockF2 | Feb 24, 2018 | F | 126,006 | $36.26 | D | 1,434,001 | D | |
| Common StockF3,F2 | Feb 24, 2018 | F | 154,058 | $36.26 | D | 1,279,943 | D | |
| Common StockF4,F5 | Feb 24, 2018 | F | 154,289 | $35.98 | D | 1,125,654 | D | |
| Common StockF4,F5 | Feb 24, 2018 | F | 157,353 | $35.98 | D | 968,301 | D | |
| Common Stock | holding | — | — | — | 11,075 | I | By Rule 16b-3 Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation Rights | $20.90 | Feb 24, 2018 | M | 420,000 | D | Feb 24, 2018 | Feb 24, 2018 | Common Stock | 420,000 | 0 | D |
| Stock Appreciation Rights | $18.90 | Feb 24, 2018 | M | 483,559 | D | Feb 24, 2018 | Feb 24, 2018 | Common Stock | 483,559 | 0 | D |
Explanation of responses
- F1The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
- F2Price is the closing price of Pfizer common stock on February 23, 2018
- F3The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
- F4The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
- F5Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.